AR007097A1 - BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents

BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.

Info

Publication number
AR007097A1
AR007097A1 ARP970101977A ARP970101977A AR007097A1 AR 007097 A1 AR007097 A1 AR 007097A1 AR P970101977 A ARP970101977 A AR P970101977A AR P970101977 A ARP970101977 A AR P970101977A AR 007097 A1 AR007097 A1 AR 007097A1
Authority
AR
Argentina
Prior art keywords
compounds
matrix
matrix metaloprotease
biarylacetilene
biarylacethylene
Prior art date
Application number
ARP970101977A
Other languages
Spanish (es)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR007097A1 publication Critical patent/AR007097A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/90Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Se presentan compuestos inhibitorios de la metaloproteasa de matriz, composiciones farmacéuticas de los mismos y el uso de dichos compuestos parapreparar un medicamento útil. Los compuestos tienen la fórmula (I), donde R15 es seleccionadoen tre el grupo que consiste en HOCH2, MeOCH2, (n-Pr)2NCH2,CH3CO2CH2, EtOCO2CH2, HO(CH2)2, CH3CO2(CH2)2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4, 3-HO-Ph, y PhCH2OCH2; y R16 es seleccionado entre las fórmulas (II). Estoscompuestos son útiles para inhibirlas m etaloproteasas de matriz y, por lo tanto, para combatir los trastornos a los cuales contribuyen las MMP, talescomo la osteoartritis, la artritis reumatoidea, la artritis séptica, las enfermedades periodontales, las úlceras decórnea, la p roteinuria, laenfermedad de aneurisma aórtico, la epidermólisis vesicular distrófica, los tratarnos que producen respuestas inflamatorias, las osteopenias en las quemedia la actividad de MMP, la enfermedad de la articulacióntemporomandibular, l as enfermedades desmielinizantes del sistema nervioso; las metástasis detumores o la pérdida degenerativa de cartílago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura deplacaateroesclerótica.Matrix metalloprotease inhibitory compounds, pharmaceutical compositions thereof, and the use of such compounds to prepare a useful medicament are presented. The compounds have the formula (I), where R15 is selected from the group consisting of HOCH2, MeOCH2, (n-Pr) 2NCH2, CH3CO2CH2, EtOCO2CH2, HO (CH2) 2, CH3CO2 (CH2) 2, HO2C (CH2) 2, OHC (CH2) 3, HO (CH2) 4, 3-HO-Ph, and PhCH2OCH2; and R16 is selected from formulas (II). These compounds are useful to inhibit matrix methaloproteases and therefore to combat the disorders to which MMPs contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal diseases, corneal ulcers, proteinuria, aortic aneurysm disease, dystrophic vesicular epidermolysis, treatments that produce inflammatory responses, osteopenias in which MMP activity mediates, temporomandibular joint disease, demyelinating diseases of the nervous system; tumor metastases or degenerative cartilage loss after traumatic joint injury; and coronary thrombosis from atherosclerotic plate rupture.

ARP970101977A 1996-05-15 1997-05-12 BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT. AR007097A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502896A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
AR007097A1 true AR007097A1 (en) 1999-10-13

Family

ID=24587368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101977A AR007097A1 (en) 1996-05-15 1997-05-12 BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.

Country Status (18)

Country Link
EP (1) EP0912496A1 (en)
JP (1) JP3090957B2 (en)
CN (1) CN1139570C (en)
AR (1) AR007097A1 (en)
AU (1) AU710759B2 (en)
BR (1) BR9709077A (en)
CA (1) CA2253796C (en)
CO (1) CO5080759A1 (en)
HN (1) HN1997000088A (en)
HR (1) HRP970245B1 (en)
ID (1) ID16910A (en)
PA (1) PA8429301A1 (en)
SV (1) SV1997000035A (en)
TN (1) TNSN97084A1 (en)
TW (1) TW381079B (en)
WO (1) WO1997043245A1 (en)
YU (1) YU18697A (en)
ZA (1) ZA974031B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AR035478A1 (en) * 1999-01-27 2004-06-02 Wyeth Corp AMIDA-HYDROXAMIC ACID, ACETYLLENE, BETA-SULPHONAMIDE AND PHOSPHINIC ACID AS INHIBITORS OF TACE, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2804918C (en) 2010-07-08 2018-03-06 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same
CN106458938A (en) 2014-04-03 2017-02-22 拜耳制药股份公司 Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
EP3126339A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (en) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Biphenylyl-butyric acid derivs. - anti phlogistics
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2253796A1 (en) 1997-11-20
CN1139570C (en) 2004-02-25
CN1225623A (en) 1999-08-11
HRP970245B1 (en) 2002-06-30
ID16910A (en) 1997-11-20
CO5080759A1 (en) 2001-09-25
WO1997043245A1 (en) 1997-11-20
HRP970245A2 (en) 1998-04-30
SV1997000035A (en) 1999-01-14
BR9709077A (en) 1999-08-03
EP0912496A1 (en) 1999-05-06
HN1997000088A (en) 1997-06-18
JPH11511179A (en) 1999-09-28
AU710759B2 (en) 1999-09-30
PA8429301A1 (en) 2000-05-24
AU2938697A (en) 1997-12-05
ZA974031B (en) 1998-02-19
YU18697A (en) 1999-11-22
TW381079B (en) 2000-02-01
CA2253796C (en) 2003-10-28
TNSN97084A1 (en) 2005-03-15
JP3090957B2 (en) 2000-09-25

Similar Documents

Publication Publication Date Title
ATE208397T1 (en) ARYL SUBSTITUTED 5.5 LINKED AROMATIC NITRO COMPOUNDS AS ANTI-INFLAMMATORY ACTIVES
AR029383A1 (en) SMALL MOLECULES, THE INTERMEDIARIES FOR THEIR SYNTHESIS, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT INTENDED FOR TREATMENT OR PROPHYLAXIS OF INFLAMMATORY DISEASES OR MEDIATIONED BY IMMUNE CELLS
BR9611015A (en) Compound, pharmaceutical composition and process for the treatment of an inflammatory disease susceptible to treatment with a non-toxic non-steroidal anti-inflammatory agent, pharmaceutically acceptable salt, use of a compound
DE60018040D1 (en) POLYMORPHIC CRYSTALLINE FORMS OF CELEKOXIB
BR0312280A (en) Compound or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof, process for preparing it, pharmaceutical composition, use of the compound, methods for producing a cholesterol absorption inhibiting effect, and for treating hyperlipidemic conditions in a warm-blooded animal, such as man, who needs such treatment, combination, and use of this
AR007097A1 (en) BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
EA200200520A1 (en) Derivatives of Heterocycloalkylsulfonylpyrazole as an Anti-Inflammatory / Analogical Agents
AR022423A1 (en) COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR007098A1 (en) MATRIX METALOPROTEASE INHIBITORS, COMPOSITIONS UNDERSTANDING THEM, AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS
MX9307608A (en) CYTOKINE RELEASE INHIBITORS AND IL-1 ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
BG102471A (en) Aromatic ketoacids and their derivatives as inhibitors of matrix metalloproteinases
ES2147629T3 (en) ALKENYL CARBOXYLIC ACID GUANIDINES REPLACED WITH A FLUOROPHENYL GROUP AS NA + / NH + EXCHANGE INHIBITORS, THEIR PREPARATION PROCEDURE AND THEIR USE AS A DIAGNOSTIC MEDICINE OR AGENT AS WELL AS THE CONTAINING MEDICINE.
AR007100A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED PHENYLALKYL COMPOUNDS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
ID28365A (en) NEW NATURAL PRODUCTS DOWN
AR007096A1 (en) MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS
ES2095894T3 (en) GALACTOMANANE DERIVATIVES FOR COATING OR INCRUSTATION OF ACTIVE PHARMACEUTICAL PRODUCTS.
AR022405A1 (en) DERIVATIVES OF PYROGLUTAMIC ACID AND RELATED COMPOUNDS THAT INHIBIT THE ADHESION OF LEUCOCITS INTERMEDIATED BY VLA-4, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF AGENTS AND MEDICINES
IL73849A (en) Pharmaceutical compositions containing phospholipids and oxicam derivatives and their production
PA8429601A1 (en) INHIBITION OF MATRIX METALOPROTEINASES BY ACIDS 2- (W-AROILALQUIL) -4-BIARIL-4-OXOBUTIRICOS.
MX9206042A (en) NEW DERIVATIVES OF TIADIAZINONES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATION CONTAINING THEM
ECSP972114A (en) BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE
ECSP972111A (en) MATRIX METALOPROTEINASES INHIBITORS BY ACIDS 2- (AROILALQUIL) -4 BIARIL-4- OXOBUTIRICOS
PT84473A (en) NOVEL SULFONAMIDES DERIVED FROM DIARYLMETHANES AND METHODS OF PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
ECSP972112A (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED FENETILE COMPOUNDS
ES2052622T3 (en) DERIVATIVES OF BENZODIOXOL, COMPOUNDS THAT INCLUDE THEM AND THEIR USE OF THEM FOR THE MANUFACTURE OF MEDICINES.

Legal Events

Date Code Title Description
FB Suspension of granting procedure